CSIMarket
 
Axsome Therapeutics Inc   (AXSM)
Other Ticker:  
 
 
Price: $75.5400 $5.80 8.317%
Day's High: $75.6 Week Perf: 6.5 %
Day's Low: $ 69.93 30 Day Perf: -19.03 %
Volume (M): 1,708 52 Wk High: $ 98.40
Volume (M$): $ 128,992 52 Wk Avg: $74.14
Open: $69.97 52 Wk Low: $55.02



 Market Capitalization (Millions $) 3,559
 Shares Outstanding (Millions) 47
 Employees 48
 Revenues (TTM) (Millions $) 223
 Net Income (TTM) (Millions $) -202
 Cash Flow (TTM) (Millions $) 189
 Capital Exp. (TTM) (Millions $) 1

Axsome Therapeutics Inc
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for Central Nervous System (CNS) disorders, including depression, chronic pain, and other neurological conditions. Established in 2012, Axsome has its headquarters in New York, United States.

The company utilizes its proprietary technology and expertise to create novel treatment approaches that offer a new option for patients suffering from CNS disorders. Axsome's core competencies include drug discovery, preclinical and clinical development, and regulatory affairs. The company leverages its strengths and partnerships in these areas to accelerate the development of its therapeutic candidates.

Axsome's portfolio includes several product candidates that are either in the development or clinical testing stage. Some notable candidates include AXS-05, AXS-07, and AXS-1 AXS-05 is a combination of dextromethorphan and an inhibitor of the monoamine oxidase enzyme. This drug is being evaluated for the treatment of major depressive disorder and treatment-resistant depression. AXS-07 is a combination of an anti-inflammatory drug and a triptan, being developed for the treatment of migraines. AXS-12, on the other hand, is being developed for the treatment of narcolepsy.

Axsome has also been actively engaged in several partnership and licensing agreements to advance its pipeline of products. In 2018, the company signed a global license agreement for AXS-05 with Pfizer, which granted them rights to develop and commercialize this product in markets outside the United States. More recently, in 2021, Axsome signed a licensing agreement with Bausch Health that will allow the latter to manufacture and commercialize AXS-07 for migraines in Canada.

The company has been rapidly growing in the past few years, with its share price increasing considerably in response to positive clinical data and regulatory approvals. Axsome has also received several awards and recognitions for its innovative work, including being named as one of the top biotech companies to work for in 2021 by BioSpace.

In conclusion, Axsome Therapeutics Inc is a leading biopharmaceutical company that focuses on the development of innovative therapies for CNS disorders. The company has an extensive portfolio of product candidates, with several in various stages of development and clinical testing. Axsome has been recognized for its innovative work in the field of CNS disorders and has also been actively engaged in strategic partnerships to boost its progress. As the company's pipeline progresses, it has the potential to make a significant impact on the treatment of CNS disorders, particularly in areas where current treatment options are inadequate.


   Company Address: One World Trade Center New York 10007 NY
   Company Phone Number: 332-3241   Stock Exchange / Ticker: NASDAQ AXSM
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Announcement

Axsome Therapeutics Generates Strong Net Revenue in Q4 2023, But Cumulative Net Loss Signals Concerns Over Financial Performance

Published Thu, Jan 4 2024 12:00 PM UTC


The preliminary financial report reveals that Axsome Therapeutics generated $71 million in net product revenue during the fourth quarter of 2023, while the net revenue for the full year amounted to $204 million. Although these numbers show a significant increase in sales and a growing market presence, they must be analyzed in the context of the company's considerable ne...

Axsome Therapeutics Inc

Axsome Therapeutics Inc Achieves Record Revenue Growth of 243.077% in Q3 2023

The stock market has been buzzing lately with exciting news from the pharmaceutical industry. One company that has caught the attention of investors is Axsome Therapeutics Inc. In the July to September 2023 period, the company announced an impressive revenue growth of 243.077% year on year, reaching a staggering $57.79 million.
This remarkable growth in revenue sets Axsome Therapeutics Inc apart from its peers in the Major Pharmaceutical Preparations industry, which only experienced a modest 1.79% top-line growth during the same period. This demonstrates the company's ability to outperform its competitors and seize new opportunities in the market.

Axsome Therapeutics Inc

Deficit Widens at Axsome Therapeutics Inc in Q2 Despite Impressive Revenue Growth; Shares Suffer 4.3% Hit

Over the past 5 trading days, the shares of Axsome Therapeutics Inc have experienced a decline of -4.32%, contributing to a year-to-date performance of 2.67%. Currently, the shares are trading on the NASDAQ at a value that is 16.3% higher than its 52-week average.
One significant announcement made by Axsome Therapeutics Inc is the substantial increase in revenue of 429.491% year on year, reaching $46.70 million in the second quarter of the 2023 earnings season. However, despite this remarkable revenue growth, there was a per-share shortfall of $-1.54. In comparison, the Major Pharmaceutical Preparations industry peers experienced a more modest 2.30% increase in top-line revenue during the same period.






 

Axsome Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com